Sector: Life Sciences

Latest content

Fujifilm unit hits upstart rival with ultrasound patent suit

New competitor litigation, coupled with significant M&A-related patent transactions, show how crucial medical imaging is to the Japanese giant's continued re-invention

14 March 2022

CJEU asked again to provide clarity on combination product SPCs

Innovators hope for certainty on articles 3(a) and 3(c) of the EU’s supplementary protection certificate regulation

11 March 2022

Medical device maker is latest to tap secondary market for wireless patents

A recent deal shows that a wider selection of corporates are exploring acquisition opportunities and working with custom R&D labs

08 March 2022

Platform technology owners demand a chunk of Moderna’s covid-19 revenues

Arbutus Biopharma and Genevant Sciences have filed suit against the vaccine innovator

07 March 2022

Broad Institute’s big US CRISPR patent win does little to clear path for Cas9 licensees

As the US and European gene-editing IP landscapes drift further apart, therapeutics companies face difficult freedom-to-operate quandaries

03 March 2022

The life science royalty sales market

Featured in Special Report 2022 Q1: Patent Dealmaking

Some of the highest-value deals in intellectual property today are taking place in the burgeoning marketplace for revenue streams linked to pharmaceutical products

02 March 2022

How manufacturing patents are shaping US biologics strategies

Study reveals the significance of manufacturing IP rights in BPCIA litigation

25 February 2022

California pay-for-delay ruling creates new pharma patent settlement headaches

Dispute resolution teams will want to steer clear of the sunshine state following a recent federal court decision

24 February 2022

Russian Supreme Court rejects Gilead’s decree challenge

In a closely watched case, the Supreme Court has upheld the Civil Code’s prioritising of people’s lives and health during the covid-19 pandemic, over profits lost to patent owners

23 February 2022

More is being done than ever before to monetise neglected pharma IP

Roivant’s most recent spinout shows that it is still on the hunt for deprioritised life sciences patents

22 February 2022

Unlock unlimited access to all IAM content